| Affymax and Takeda Confirm U.S. Registration Strategy for Investigational Drug ... - MarketWatch (press release) |
|
|
MarketWatch (press release) "Our plan is to pursue approval of peginesatide for the treatment of anemia in CRF patients on dialysis," said Arlene M. Morris, chief executive officer of |